Show simple item record

dc.contributor.authorParnell, E.*
dc.contributor.authorPalmer, Timothy M.*
dc.contributor.authorYarwood, S.J.*
dc.date.accessioned2015-05-01T13:37:18Z
dc.date.available2015-05-01T13:37:18Z
dc.date.issued2015
dc.identifier.citationParnell E, Palmer TM and Yarwood SJ (2015) The future of EPAC-targeted therapies: agonism versus antagonism. Trends in Pharmacological Sciences. 36(4): 203-214.en_US
dc.identifier.urihttp://hdl.handle.net/10454/7171
dc.descriptionyesen_US
dc.description.abstractPharmaceutical manipulation of cAMP levels exerts beneficial effects through the regulation of the exchange protein activated by cAMP (EPAC) and protein kinase A (PKA) signalling routes. Recent attention has turned to the specific regulation of EPAC isoforms (EPAC1 and EPAC2) as a more targeted approach to cAMP-based therapies. For example, EPAC2-selective agonists could promote insulin secretion from pancreatic β cells, whereas EPAC1-selective agonists may be useful in the treatment of vascular inflammation. By contrast, EPAC1 and EPAC2 antagonists could both be useful in the treatment of heart failure. Here we discuss whether the best way forward is to design EPAC-selective agonists or antagonists and the current strategies being used to develop isoform-selective, small-molecule regulators of EPAC1 and EPAC2 activity.en_US
dc.language.isoenen_US
dc.rights© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).en_US
dc.subjectExchange protein activated by cAMP; EPAC; cAMP; Inflammation; Diabetes; Agonism; Antagonismen_US
dc.titleThe future of EPAC-targeted therapies: agonism versus antagonismen_US
dc.status.refereedYesen_US
dc.typeArticleen_US
dc.type.versionpublished version paperen_US
dc.identifier.doihttps://doi.org/10.1016/j.tips.2015.02.003
refterms.dateFOA2018-07-25T11:18:25Z


Item file(s)

Thumbnail
Name:
TIPS2015.pdf
Size:
2.161Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record